about Michele Park, Ph.D.:
Michele Park, Ph.D., serves as a Partner at Clarus. Dr. Park joined Clarus in 2006 with five years of sell-side equity research experience covering the biotechnology sector. From 2002-2005, Dr. Park was a research analyst at Credit Suisse First Boston, where she covered biotechnology stocks as a member of the firm’s US biotechnology team. Before joining CSFB, Dr. Park was a biotechnology research analyst at US Bancorp Piper Jaffray. Dr. Park received a Ph.D. in Molecular Biology from Cornell University’s Graduate School of Biomedical Sciences, completing her Ph.D. dissertation at Memorial Sloan-Kettering Cancer Center, and a BA in Molecular Biology from Princeton University.
Dr. Park has served on the Lumos Board since 2016.